In the BioHarmony Drug Report Database

"Preview" Icon

Erenumab-aooe

Aimovig (erenumab) is an antibody pharmaceutical. Erenumab was first approved as Aimovig on 2018-05-17. It has been approved in Europe to treat migraine disorders. It is known to target calcitonin gene-related peptide type 1 receptor.

 

Trade Name

 

Aimovig
 

Common Name

 

erenumab
 

ChEMBL ID

 

CHEMBL3833329
 

Indication

 

migraine disorders
 

Drug Class

 

Monoclonal antibodies: fully human, neural indications

Image (chem structure or protein)

Erenumab-aooe structure rendering